Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

[1]  R. Plummer,et al.  Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers , 2007, Clinical Cancer Research.

[2]  G. Cavet,et al.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL , 2007, Nature Medicine.

[3]  Xiaoping Zhang,et al.  Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. , 2007, Cancer letters.

[4]  A. Tolcher,et al.  Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Erinna F. Lee,et al.  Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.

[6]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  D. Buchsbaum,et al.  TRAIL receptor-targeted therapy. , 2006, Future oncology.

[8]  S. Fulda,et al.  Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy , 2006, Oncogene.

[9]  D. Lawrence,et al.  Death-receptor activation halts clathrin-dependent endocytosis , 2006, Proceedings of the National Academy of Sciences.

[10]  Andreas Untergasser,et al.  Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs , 2006, Clinical Cancer Research.

[11]  Yabin Guo,et al.  A Novel Anti-human DR5 Monoclonal Antibody with Tumoricidal Activity Induces Caspase-dependent and Caspase-independent Cell Death* , 2005, Journal of Biological Chemistry.

[12]  E. Rowinsky.  Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Cohen,et al.  TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. , 2005, Cancer research.

[14]  S. Fesik.  Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.

[15]  M. Andreeff,et al.  Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell death , 2005, British journal of haematology.

[16]  M. Fiscella,et al.  HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo , 2005, British Journal of Cancer.

[17]  C. Ware,et al.  Enhanced Apoptosis and Tumor Regression Induced by a Direct Agonist Antibody to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor 2 , 2005, Clinical Cancer Research.

[18]  Karen Billeci,et al.  Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling* , 2005, Journal of Biological Chemistry.

[19]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[20]  S. Fulda,et al.  Targeting apoptosis pathways in cancer therapy. , 2004, Current cancer drug targets.

[21]  Geoffrey S Ginsburg,et al.  Targeted therapies for cancer 2004. , 2004, American journal of clinical pathology.

[22]  A. Ashkenazi,et al.  Targeting death receptors in cancer with Apo2L/TRAIL. , 2004, Current opinion in pharmacology.

[23]  C. Eigenbrot,et al.  High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. , 2004, Journal of molecular biology.

[24]  I. Ishida,et al.  Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2 , 2004, Cell Death and Differentiation.

[25]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[26]  A. Strasser,et al.  The role of the Bcl-2 protein family in cancer. , 2003, Seminars in cancer biology.

[27]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[28]  G. Salvesen,et al.  Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.

[29]  A. Ashkenazi,et al.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.

[30]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[31]  D. Green,et al.  The machinery of programmed cell death. , 2001, Pharmacology & therapeutics.

[32]  Z. Wang,et al.  Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.

[33]  H. Koeppen,et al.  Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4 , 2001, The Journal of Immunology.

[34]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[35]  M. Ultsch,et al.  A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. , 2000, Biochemistry.

[36]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[37]  D. Stuart,et al.  Structure of the TRAIL–DR5 complex reveals mechanisms conferring specificity in apoptotic initiation , 1999, Nature Structural Biology.

[38]  M. Ultsch,et al.  Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. , 1999, Molecular cell.

[39]  B. Oh,et al.  2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. , 1999, Immunity.

[40]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[41]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[42]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[43]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[44]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[45]  A. Gurney,et al.  A novel receptor for Apo2L/TRAIL contains a truncated death domain , 1997, Current Biology.

[46]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[47]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[48]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[49]  M. L. Eilert,et al.  A method for storing controls for prothrombin-time determinations. , 1952, American journal of clinical pathology.

[50]  J. Ross.  Targeted Therapies for Cancer , 2010 .

[51]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[52]  Thomas A. Kunkel,et al.  Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.